Canaria Bio (CEO Nahanik) announced on the 13th that it has signed an exclusive sales and license agreement with Specialised Therapeutics, an Australian pharmaceutical company specializing in anticancer drugs, for the commercialization of the ovarian cancer immuno-oncology drug Oregobomab in seven countries in Southeast Asia, including Australia and New Zealand.


Carlo Montagner, CEO of ST, said, "ST has a portfolio of anticancer drugs targeting various solid tumors except ovarian cancer, and now Oregobomab has become our first ovarian cancer treatment."


Nahanik, CEO of Canaria Bio, said, "ST is specialized in the commercialization of anticancer drugs, and based on strong relationships with prominent oncologists in the region, we believe they will lead the commercial success of Oregobomab."


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

The ovarian cancer immuno-oncology drug Oregobomab showed encouraging results in Phase 2 clinical trials, with a progression-free survival (PFS) extended by 30 months to 42 months compared to the existing standard treatment. Additionally, the hazard ratio for overall survival (OS) was 0.35, which was significantly better than the PFS hazard ratio of 0.46. Currently, Canaria Bio is developing the ovarian cancer treatment Oregobomab through its 100% subsidiary Canaria Bio (formerly MHC&C).


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing